This article is more than 5 years old. Information may no longer be current.
VIDEO: HOPE-3 demonstrates proof of polypill concept
Click Here to Manage Email Alerts
CHICAGO — In this video exclusive, Jackie Bosch, PhD, provides investigator insight on the HOPE-3 trial.
The 12,000-patient trial assessed outcomes of treatment with cholesterol and BP-lowering drugs in a globally diverse population at intermediate risk for developing CVD. Researchers studied the effectiveness of rosuvastatin (Crestor, AstraZeneca) 10 mg/day and candesartan 16 mg/day plus hydrochlorothiazide 12.5 mg/day, as well as a combination of the two therapies, for the reduction of CV events in patients at intermediate risk for CVD.
According to the results of the three-arm trial, lowering cholesterol with statins significantly reduced adverse CV events in people with average cholesterol and BP levels who were considered to be at intermediate risk for CVD, while the use of BP-lowering medications was beneficial only in those with higher BP levels.
“What this means for clinical practice is that it’s easy to implement the polypill concept because there is very little effort required to monitor as things go along. The drugs are safe,” said Bosch, associate professor of rehabilitation science at McMaster University and director of the prevention program at the Population Health Research Institute.